The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pilot study to test safety and efficacy of avelumab in small bowel adenocarcinoma (SBA).
 
Dana Backlund Cardin
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals
Research Funding - Advaxis (Inst); Advaxis (Inst); Advaxis (Inst); Advaxis (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Synta (Inst); Synta (Inst); Synta (Inst); Synta (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie
 
Jennifer Whisenant
Research Funding - EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst)
Patents, Royalties, Other Intellectual Property - I am listed as an inventor on a patent licensed to Anasys Instruments.; I am listed as an inventor on a patent licensed to Anasys Instruments.; I am listed as an inventor on a patent licensed to Anasys Instruments.; I am listed as an inventor on a patent licensed to Anasys Instruments.
 
G. Dan Ayers
No Relationships to Disclose
 
Jill Gilbert
Leadership - American Board of Internal Medicine (ABIM); American Board of Internal Medicine (ABIM); American Board of Internal Medicine (ABIM); American Board of Internal Medicine (ABIM); Tennessee Oncology; Tennessee Oncology; Tennessee Oncology; Tennessee Oncology
Honoraria - Bayer; Bayer; Bayer; Bayer; Sanofi; Sanofi; Sanofi; Sanofi; TRM Oncology; TRM Oncology; TRM Oncology; TRM Oncology; UpToDate; UpToDate; UpToDate; UpToDate
Consulting or Advisory Role - ASCO; ASCO; ASCO; ASCO; Bayer; Bayer; Bayer; Bayer; CUE Biopharma; CUE Biopharma; CUE Biopharma; CUE Biopharma; EPIC; EPIC; EPIC; EPIC; IRX Therapeutics; IRX Therapeutics; IRX Therapeutics; IRX Therapeutics; Sanofi; Sanofi; Sanofi; Sanofi
Research Funding - amgen (Inst); amgen (Inst); amgen (Inst); amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals; Threshold Pharmaceuticals
 
Kimberly Brown Dahlman
Stock and Other Ownership Interests - Medivation (I); Medivation (I); Medivation (I); Medivation (I)
Consulting or Advisory Role - Kadmon; Kadmon; Kadmon; Kadmon
Research Funding - Kadmon; Kadmon; Kadmon; Kadmon
 
Chanjuan Shi
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie
 
Jordan Berlin
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Arno Therapeutics; Arno Therapeutics; Arno Therapeutics; Arno Therapeutics; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer Health; Bayer Health; Bayer Health; Bayer Health; Celgene; Celgene; Celgene; Celgene; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; ipsen; ipsen; ipsen; ipsen; lsk biopharma; lsk biopharma; lsk biopharma; lsk biopharma; qed therapeutics; qed therapeutics; qed therapeutics; qed therapeutics; Seagen; Seagen; Seagen; Seagen
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); boston biomedical (Inst); boston biomedical (Inst); boston biomedical (Inst); boston biomedical (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); pfizer (Inst); pfizer (Inst); pfizer (Inst); pfizer (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); PsiOxus Therapeutics (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie; Bayer; Bayer; Bayer; Bayer; boston Biomedical; boston Biomedical; boston Biomedical; boston Biomedical; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Seagen; Seagen; Seagen; Seagen
Other Relationship - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca